Refine by
Vaccine Designed Articles & Analysis
36 news found
Creative BioMart, a biotechnology company focused on protein-related research solutions, has recently upgraded its epitope mapping service to better support researchers in therapeutic antibody development, vaccine design, and immunogenicity studies. The updated platform integrates multiple experimental approaches with customizable strategies, enabling more ...
Protheragen focuses on delivering comprehensive vaccine development services, specifically designed to meet the distinct challenges presented by various pathogens. ...
The development of vaccines against superbugs is an important area of research because vaccines can help prevent infections from occurring in the first place and reduce the need for antibiotics. ...
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. ...
ByOncoVITA
CEPI will provide seed funding of up to US$4.8m to NEC OncoImmunity AS (NOI), a Norway-based subsidiary of NEC, which specializes in artificial intelligence-driven biotechnology, to support the initial development of broadly protective betacoronavirus vaccine candidates. NEC, through NOI, will lead a research consortium including the European Vaccine Initiative ...
CD BioGlyco, a biotechnology company specialized in the field of glycobiology, has developed a series of advanced vaccine development platforms by integrating various advanced technologies to promote the development of glycol-based vaccines. ...
FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients Next steps for development of VBI-1901 : Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated approval application Q4 2022: Expected initiation of randomized, controlled evaluation in primary GBM ...
VAX-A1: Vaxcyte continues to advance development of VAX-A1, a novel conjugate vaccine designed to prevent infections caused by Group A Streptococcus (Strep) bacteria, and expects to provide guidance for its anticipated IND application submission to the FDA in the second half of 2022. VAX-PG: Vaxcyte expects to nominate a final vaccine candidate ...
(Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. ...
ByVaxxinit
(Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 8:30 a.m. ...
UBS Global Healthcare Conference May 23-25, 2022; New York, NY One-on-one meetings will take place on Tuesday, May 24 and Wednesday, May 25. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel ...
(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Cancer Research UK recently completed patient enrollment in the ongoing Phase 1 clinical trial of VAC2, an allogeneic cancer vaccine product candidate, for the treatment of non-small cell lung cancer (“NSCLC”). ...
Data on mix-and-match combinations of vaccines – like those being assessed in this trial - will contribute to the design of flexible vaccination strategies aimed at controlling COVID-19 and combatting emerging SARS-CoV-2 variants. ...
ByVaxxinit
(Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 12:45 p.m. ...
Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned Company Expects to Announce Topline Results from Both the Phase 1 and Phase 2 Portions of the Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia by the End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate ...
Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection Vaxcyte, Inc. ...
The approach was published in the peer review journal HLA where the first author Anzar and her colleagues also demonstrated how the approach led to the discovery of a new officially named HLA allele, from standard sequencing data routinely used in the design of personalized cancer vaccines. “This approach is an important development in the field of ...
This newly identified pattern may help predict which strains will become variants of concern and inform future vaccine design. “As the COVID-19 pandemic continues to evolve, it is extremely important for our scientific community to begin to understand how a virus like SARS-CoV-2 manages to adapt its genome over time,” said Venky Soundararajan, ...
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it has commenced an underwritten public offering of its common stock and pre-funded warrants. ...
Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide Broad-Spectrum Protection Vaxcyte, Inc. ...